Diabetic macular edema (DME) is a signi icant cause of diabetic retinopathy and a major cause of vision loss. In this study, we aimed to evaluate and compare the ef icacy of two injectable drugs; intravitreal A libercept and intravitreal Ranibizumab for the treatment of DME of the eyes. A retrospective chart review was conducted for patients diagnosed with DME from March 2014 to January 2019 who received either intravitreal A libercept or intravitreal Ranibizumab injection. A total of 57 eyes were included, of which 19 eyes were treated with intravitreal Ranibizumab injection, and 38 eyes were treated with intravitreal A libercept injection; all eyes were examined for 3 months. Two outcomes were assessed in this study, namely; visual acuity (VA) and central macular thickness (CMT). The mean age in the Ranibizumab group was 61.1±9.5 vs 64.3±10.2 in the A libercept group with no significant difference (p-value=0.25). The ratio of improvement in visual acuity (VA) in the Ranibizumab group was 68.4% vs 44.7% in the A libercept group; (p-value=0.038) which demonstrates the superiority of Ranibizumab over A libercept concerning visual acuity result. However, there is no statistically signi icant difference between the ratio of improvement in central macular thickness (CMT) results in both groups; (p-value=1.00). In fact, the ratio of improvement in CMT in both groups was the same 78.9% for both the groups. The pre and post results demonstrated improvement in post-procedural for CMT among both the groups but only Ranibizumab group showed VA improvement post-procedural. Through this study, we concluded that both injectable drugs improve visual acuity (VA) and decrease central macular thickness (CMT) in eyes with DME. However, Ranibizumab is superior in improving visual acuity compared to A libercept. Further comparative effectiveness trials between A libercept and Ranibizumab are still warranted.
INTRODUCTION
Diabetic Macular Edema is the most signi icant vascular complication among diabetic patients that could lead to blindness if it remains untreated. Ophthalmic problems such as corneal abnormalities, glaucoma, iris neovascularization, cataracts, and neuropathies are generally very common among diabetic patients. (Cohen and Gardner, 2016) However, the condition of DME is of much concern as if untreated. It can cause vision loss among diabetic patients. (Cohen and Gardner, 2016; Ciulla et al., 2003) . DME occurs as the advantage stage of diabetic retinopathy that is characterized by abnormal growth of blood vessels within retina for compensating the oxygen demand of ischemic retina. If remain untreated or progressive, it may lead to DME, which further involves retinal thickening in the macular area. (Ciulla et al., 2003) Hypothesis and literature proposed that expanded penetrability of retinal veins permit exudation and gathering of extracellular liquid in the retinal layers which further breakdown the blood-retinal layer because of expanded vascular porousness and which further prompts pathogenesis and development of Macular Edema. (Dugel et al., 2016; Shah and Heier, 2016) .
The treatment strategies of DME have evolved in the recent times and with the advancement in techniques and with further clari ication of pathophysiology intravitreal injections of vascular endothelial growth factor (VEGF) antibodies are becoming preferable for the treatment worldwide. (Călugăru and Călugăru, 2016) A libercept, bevacizumab, and ranibizumab are anti-VEGF agents who are reported to be effective for the treatment however only a libercept and ranibizumab have been approved by Food and Drug Administration (FDA) for the treatment of DME. (Nguyen et al., 2012 (Nguyen et al., , 2010 The mode of action of these 2 drugs is different; however, they both act on VEGF and improve visual acuity. However, ranibizumab binds to all the isoforms of human VEGF-A while a libercept binds to all isoforms of VEGF-A, VEGF-B, and placental growth factor. (Ophthalmology, 2007; Ishibashi et al., 2015; Korobelnik et al., 2014; Mitchell et al., 2011) In the recent times, various clinical trials and observational studies approved the ef icacy of these injectable drugs, for instance, Sameh Mosaad Fouda et al. in 2017 reported that in patients with moderate vision loss there was no difference in the ef icacy of intravitreal a libercept and ranibizumab in the treatment of diabetic macular edema (DME). (Fouda and Bahgat, 2017) Few studies (Rhoades et al., 2017; Oshitari et al., 2016) have reported ef icacy of one drug more than the other for instance Norihiro Shimizu et al. in 2017 reported that for best-corrected visual acuity and for reducing central macular thickness (CMT) in eyes with DME intravitreal a libercept as more effective compared to ranibizumab. (Oshitari et al., 2016) Likewise, Wykoff CC et al. in 2014 conducted a clinical trial, reported superiority of a libercept by stating that 2.0 mg treatment with a libercept maintained mean visual acuity improvements in recalcitrant exudative age-related macular degeneration patients. (Wykoff et al., 2014) By keeping into the consideration of the differences in the ef icacy of a libercept and ranibizumab, we aimed to compare the effectiveness of a libercept and ranibizumab for the treatment of DME in eyes among diabetic patients
MATERIALS AND METHODS

Study setting and study design
A retrospective chart review was conducted for patients diagnosed with DME to compare the ef icacy of intravitreal a libercept and ranibizumab. The data were collected from the Security Forces Hospital and King Faisal Specialist Hospital & Research Center in the ophthalmology clinics, Riyadh, Saudi Arabia.
Population and Study Sample
Diabetic patients reported with DME from March 2014 to January 2019 who received either intravitreal A libercept or intravitreal Ranibizumab injection were recruited for this study. A total of 57 eyes were included, 19 eyes were treated with intravitreal ranibizumab injection of 0.5 mg/0.1 mL (Group A) and 38 eyes treated with intravitreal a libercept injection of 2 mg/0.05 mL (Group B). Visual acuity (VA) and central macular thickness (CMT) were reported for each eye at 3 months.
Ophthalmic examination
All patients got a complete ophthalmic examination, including measurement of BCVA, slit-lamp examination, and dilated fundus examination. Heidelberg Spectralis-OCT (Heidelberg Engineering, Heidelberg, Germany) was performed for all eyes for macular examination. Macular thickness map with follow-up software used to detect and measure the changes in central macular thickness (CMT).
Procedure for intravitreal injection
All the patients received either a libercept (Eylea) or ranibizumab (Lucentis) at baseline and every month for 3 months as three intravitreal injections are needed as a loading dose. In case of persistent macular edema or worsening of the visual acuity or the CMT patients were reinjected with the Anti-VEGF agent. Before giving the intravitreal injection, both groups A and B received topical anesthesia (0.4% Benoxinate eye drops). The anti-VEGF agent was injected by using 27 gauge needle into the vitreous cavity. Patients were evaluated for vision performance at the end of the procedure. All patients were monitored every month for 3 months, and BCVA and CMT were reported at baseline and at follow up visits.
Inclusion and Exclusion criteria:
We included only those patients who have type I and II diabetes. Patients having clinically diagnosed and OCT (optical coherence tomography) diagnosed DME. Best-corrected visual acuity (BCVA) was ranged from 0.1 to 0.25, and having central edema of 1 mm. We only included those patients who had to follow up of at least 3 months. We excluded all the eyes with vascular retinal disorders other than diabetic retinopathy (e.g., choroidal neovascularization). We also excluded those who have received intravitreal injection previously and have a history of intraocular surgery. We also excluded patients with proliferative diabetic retinopathy and having edema of more than 1 mm. (Figure 1) 
Figure 1: Flow
Ethics and Human Subjects Issues:
All participants included in the study have provided oral and written consent. Name and any identi ication of patients were kept in privacy, and all the indings are reported without indicating the identity of any individual. Data were collected after taking ethical approval from the respective committee.
Statistical analysis:
We used SPSS version 20 for data analysis. Data were cleaned and checked for missing values before data analysis. Frequency and percentages are reported for categorical variables like gender and mean and standard deviation for continuous vari-able. Chi-square test was used to test the difference in improvement rate between the two drugs. Findings are present in tabular and graphical form. Paired t-test was used to test the difference between pre and post values for each drug. Any test was considered signi icant for p-value equal and less than 0.05. Table 1 demonstrated baseline characteristics of the study population. The mean age in Group A was 61.1±9.5 while it was 64.3±10.2 in Group B, with no signi icant difference (p-value = 0.25). The two groups had nearly the same distribution of characteristics concerning age, gender, injected eye, medication and DME duration. Table 2 demonstrated an improvement in visual acuity among the two groups. Our results demonstrated that group A receiving Ranibizumab has a signi icantly higher number of improved cases compared to group B, that is 68.4% compared to 44.7% respectively. Also, the ratio of worsened eyes was only 5.3% in Ranibizumab group while it was 36.8% in the A libercept group. However, no difference was found between the ratio of improvement in CMT results in both groups at p-value=1.00. (Table 2 ) Table 3 demonstrated that for both groups, there was a signi icant decrease in CMT values posttreatment with p-value 0.009 and0.001 for Group A and B respectively while only the Group A showed a signi icant increase in VA values post-treatment (pre: 0.26 vs post: 0.41, p-value: 0.001).
RESULTS AND DISCUSSION
The present study aimed to evaluate and compare the two drugs, intravitreal A libercept and Ranibizumab in the treatment of diabetic macular edema (DME) in the eyes. This study reported the superiority of Ranibizumab over A libercept concerning VA improvement as the improvement in VA was signi icantly higher in the group treated by Ranibizumab compared to the group treated by A libercept.
As for improvement in CMT, both groups showed the same performance with no major difference between the two groups and improvement in the eyes was same for both groups. This result are in line with the indings of the study conducted by Sameh Mosaad Fouda et al (Fouda and Bahgat, 2017) who found same effect between the two drugs concerning CMT improvement however that study also reported no difference between the two drugs concerning VA improvement which is in contrast to the indings of our study.
The superiority of Ranibizumab over A libercept concerning VA improvement concluded by the (Wykoff et al., 2014; Oshitari et al., 2016; Rhoades et al., 2017) The differences could be because of type of study design, sample size and baseline characteristics of the participants.
A study conducted by Wells et al. reported the differences in the drug ef icacy could be because of the difference in baseline visual acuity however we took all the participants with visual acuity between 0.25 -1 for which most of the studies have shown improvement post-treatment from A libercept compared to other Anti-VEGF agents. (Heier et al., 2016; Network et al., 2015) In contrary to the indings of the aforementioned studies, our study found Ranibizumab superior in improving visual acuity compared to A libercept.
The indings of this study should be concluded by keeping in mind the following limitations; 1: small sample size because of this, we cannot generalize the indings of our study. Secondly, both the groups were having a different number of participants as the nature of the study design was retrospective. We could only include available data. Although many clinical trials have been done in recent years showing the ef icacy of one drug over the other while keeping in consideration the indings of current studies we would suggest further trials with large sample size and reasonable follow up period should be conducted for comparing the effectiveness of various Anti-VEGF agents.
CONCLUSIONS
Through this study, we concluded that both the drugs are bene icial for improving visual acuity (VA) and for reducing central macular thickness (CMT) in eyes with DME. However, Ranibizumab is superior in improving visual acuity compared to A libercept. Further clinical trials between A libercept and Ranibizumab are still warranted.
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